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Abstract
Background: Open-label, randomized controlled trials (RCTs) are subject to observer bias. If patient management
is conducted without blinding, a difference between groups may be explained by other factors than study
treatment. One factor may come from taking concomitant treatments with an efficacy on the studied outcomes. In
type 2 diabetes, some antihypertensive or lipid-lowering drugs are effective against diabetic complications. We
wanted to determine if these concomitant treatments were correctly reported in articles of RCTs on type 2
diabetes and if they might have influenced the outcome.
Methods: We performed a systematic review using Medline, Embase, and the Cochrane Library (from January
1950 to July 2010). Open-label RCTs assessing the effectiveness of intensive blood-glucose control in type 2
diabetes were included. We chose five therapeutic classes with proven efficacy against diabetes complications:
angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (AIIRAs), fibrates, statins,
and aspirin. Differences between concomitant treatments were considered statistically significant when
p < 0.05.
Results: A total of eight open-label RCTs were included, but only three (37.5%) of them published
concomitant treatments. In two studies (ACCORD and ADVANCE), a statistically significant difference was
observed between the two groups for aspirin (p = 0.02) and ACEIs (p = 0.02).
Conclusions: Few concomitant treatments were published in this sample of open-label RCTs. We cannot
completely eliminate an observer bias for these studies. This bias probably influenced the results to an extent
that has yet to be determined.
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Background
In patients with type 2 diabetes (T2D), the efficacy of
blood-glucose control is generally based on the UKPDS
study [1]. The main results of this randomized study were
published in 1998 and led to international guidelines on
the treatment of type 2 diabetes [2]. It showed the efficacy
of intensive blood-glucose control on the onset of micro-
vascular complications. And also showed that metformin
was efficacious against macrovascular complications and
overall mortality in overweight patients [3]. However, even
though UKPDS was randomized, this study is controver-
sial because of its methodology and the publication of its
results [4-6]. There was a risk of observer bias because the
open-label study did not have any placebo group. The first
potential problem lies in differences in the care manage-
ment between the two groups throughout the study,
combined with an imbalance in the prescription of con-
comitant treatments that may have influenced outcome
measures [7]. This risk of bias, which is particularly high
in open-label studies, can also occur in placebo-controlled,
double-blind RCTs. For example in the FIELD study [8],
the intake of statins is much bigger in the placebo group
(36% vs 19%, p < 0.0001), which could partly explain why
there is no significant difference for the primary endpoint.
The consequences of such an imbalance in concomitant
treatments between study groups may be particularly
important since the studied outcomes are influenced by
these treatments. In T2D, some antihypertensive and
cholesterol-lowering drugs are effective against micro-
vascular complications [9,10] and/or cardiovascular mor-
tality [11,12]. Similarly, aspirin has a proven efficacy
against the risk of having a coronary event in high-risk
cardiovascular patients [13]. Because of this, we wondered
how these concomitant treatments were reported in
clinical trials on intensive blood-glucose control treat-
ments in T2D. Our objective was also to compare con-
comitant treatments prescribed in each group in order to
assess the possible confounding effect they may have had.
Methods
We previously performed a systematic review using
Medline, Embase, and the Cochrane Library (from January
1950 to July 2010). RCTs which were randomized, asses-
sing the efficacy of intensive glucose lowering treatment
(oral or insulin) versus a standard treatment (standard
care), less intensive glycaemic lowering treatment, or
placebo (intensive glycaemic treatment could be defined
either by a specified HbA1c target or by treatment inten-
sification); trials using clinically relevant outcomes; and
participants aged 18 or older with type 2 diabetes were in-
cluded [14]. We analyzed the articles and supplemental
documents (web appendices) of RCTs included in our
meta-analysis that evaluated the efficacy of intensive
blood-glucose control [14]. We especially looked for the
intake of ACEIs, AIIRAs, fibrates, statins, and aspirin
which have a proven efficacy on diabetic complications
[9-13]. When the p-value for concomitant treatments was
not specified in the publications, it was directly calculated
and a statistical significance of 0.05 was determined. Au-
thors were contacted for additional data when necessary.
Results
A total of eight open-label RCTs were found with the
systematic review [1,3,15-20]. Only two publications
specified concomitant treatments received by patients
during the study. However, they did not publish data
about all five therapeutic classes of interest (see the
ACCORD and ADVANCE studies in Table 1) [18,19].
We contacted the authors of all trials, and received ad-
ditional data from one study [16] (see Table 2). In total,
only three studies (37,5%) reported data about concomi-
tant treatments. In the ADVANCE study, data is only
available on 86% of included patients [18]. There is a
statistically significant difference (p = 0.02) in taking
aspirin, which was more prescribed in the intensively
treated group (Table 3). In the ACCORD study, data is
available for 96% of included patients [19]. The intake of
ACEIs is significantly more frequent in the conventional
treatment group (p = 0.02) (Table 3). In the Kumamoto
study, there was no statistically significant difference bet-
ween groups (Table 3) [21].
Discussion
Our study highlights the lack of publications on conco-
mitant treatments in trials assessing intensive blood-
glucose control treatments in T2D. Only three out of eight
RCTs (37.5, the ACCORD, ADVANCE, and Kumamoto
(after direct contact with authors) studies reported the
intake of these treatments without specifying the drugs,
even though their efficacy on outcome measures had been
proven. In two studies (ACCORD and AVANCE), statisti-
cally significant differences at 5% were seen in both groups
treated with specific medications without controlling to
what extent they influence study results. This lack of data
is harmful, because the interpretation of study results may
Table 1 Concomitant treatments published in study
reports
ADVANCE [17] ACCORD [18]






ACEIs angiotensin-converting enzyme inhibitors.
ARBs angiotensin-receptor blockers.
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be distorted and lead to incorrect recommendations for
clinical practice. Pooling proportions of cointerventions
and looking for an interaction between differences in
cointerventions and the effect of glycemic control on out-
comes is feasible using meta-analysis and meta-regression
techniques. This would help us reach our second objec-
tive, "if concomitant treatments are reported in clinical
trials, to assess their possible confounding effect on out-
come." However, this would require a minimum of 5 trials
for each covariate. We were only able to retrieve data on
concomitant treatments for three trials (two published
and one obtained from the authors). Therefore, we felt
that meta-regression would not be appropriate and would
give unrobust results [22].
The example of UKPDS 33 [1] is a prime example of
this. When it was published in The Lancet in 1998, it
showed that intensive blood-glucose control was effec-
tive against the onset of microvascular complications
and long-term macrovascular complications. Yet, the
only outcome with a statistically significant change was
the “retinal photocoagulation” outcome: RR = 0.71;
CI 95% [0.53-0.96]. This outcome was added during the
study and let the authors conclude that the treatment was
effective against all diabetic complications: “any diabetes-
related endpoints” (RR = 0.88 ; CI 95% [0.79-0.99]). There
was also a difference in blood pressure (BP) between some
groups: at six-year follow-up, the chlorpropamide-
treated group showed a mean BP that was much higher
than other groups (143/82 mmHg vs 138/80 mmHg,
p < 0.001). UKPDS authors emphasized that the propor-
tion of patients treated with an antihypertensive drug
was different (p = 0.022) depending on the group: 43%
for the chlorpropamide-treated group compared to 34%,
36% and 38% in other groups (respectively due to life-
style and diet guidelines, glibenclamide, and insulin).
Yet, UKPDS 38 [8] showed that treating BP could help
reduce the risk of developing diabetic retinopathy. The
double-blind, placebo-controlled DIRECT-2 RCT also
showed that candesartan increases the rate of retino-
pathy regression in T2D by 34% (RR = 1.34; CI 95%
(1.08-1.68)) [23]. In insulin-dependent (ID) diabetes,
enalapril and losartan also proved to be effective on dia-
betic retinopathy regardless of BP (OR = 0.35 : CI 95%
[0.14-0.85], OR = 0.30 ; [0.12-0.73] respectively) [24].
The FIELD [9] and ACCORD-Lipid [25] studies (two
double-blind placebo-controlled RCTs) showed that
fenofibrate was effective on retinopathy in T2D, regard-
less of the decrease in serum lipids. The efficacy of
fenofibrate on this outcome measure seemed even
higher than for blood-glucose control. Since UKPDS 34
was published, metformin has been considered to be the
most effective treatment for overweight patients with
T2D [3]. For overall mortality, the risk ratio of metfor-
min compared to lifestyle and diet guidelines was 0.64,
CI 95% [0.45-0.91]. However, a recent meta-analysis
showed that metformin was not necessarily more effect-
ive than other treatments [26]. So, the positive result
observed in UKPDS 34 may just be artificial, especially
since in the same study, only the combination of met-
formin and sulfonamides was deleterious compared to
sulfonamides alone (for overall mortality: RR = 1.6,
CI 95% [1.02-2.52]). It would have been essential to
know which concomitant treatments were present in
this study. In a letter to the authors of UKPDS after the
10-year follow-up publication, the question of concomitant
Table 2 Concomitant treatments in the Kumamoto study













ACEIs angiotensin-converting enzyme inhibitors.
ARBs angiotensin-receptor Blockers.









-Antihypertensive drugs 88.9 88.4 0.44




-Aspirin 57 54.9 0.02
-Other anti-aggregating drugs 7.1 6.2 0.07
ACCORD [18]
-Anti-hypertensive drugs 91 92 0.06
-ACEIs 69.7 71.9 0.02
-Beta blockers 47.5 48.6 0.27
-Statins 88 87.6 0.54
-Aspirin 75.5 75.5 0.98
Kumamoto [16] 11 11 1
-Statins 3.6 5.4 0.66
-Fibrates 0 0 -
-Aspirin 1.8 3.6 0.60
- Antiplatelet therapy 12.7 18.1 0.45
-ACEI 0 -
-ARB
ACEI angiotensin-converting enzyme inhibitors.
ARB angiotensin-receptor blockers.
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treatments came up: “Information on accompanying treat-
ment during the study is necessary in order to interpret
the mortality data.” [27] Surprisingly, UKPDS authors did
not respond to this [28].
A lack of blinding may overestimate the effect studied
from 17% to 34% [29-31]. However, not blinding can also
lead to a lack of difference because the control group does
not “stay constant.” For instance, the MRFIT study
observed the effect of the multifactorial care management
of cardiovascular risk on 12,000 patients compared to
usual care. After seven years of follow-up, no difference
between patient groups was observed for overall mortality
or coronary events. One of the authors’ hypotheses was
that the control group (usual care) had changed its health
habits. Smoking had dropped from 59% to 46%, diastolic
BP from 91 to 84 mmHg, and antihypertensive drug
intake had increased from 19% to 47%. Because the
cardiovascular risk of this control group decreased, the
study had insufficient statistical power and could not
demonstrate a statistically significant difference [32].
Yudkin [33] and Gale [34] call this phenomenon the
“Hawthorne effect”: the study itself may change patients’
and doctors’ behavior. This is more of a problem in open-
label studies where patients and doctors know what the
study drug is. So it is appropriate that CONSORT 2010
recommends in Section 11b (on the blinding of RCTs)
that co-intervention similarities [35] must be described
and verified, which was not required in 2001 [36]. Con-
cerning T2D treatment, the demonstration of blood-
glucose control efficacy seems to be affected by the lack of
publications on concomitant treatments whose effect on
diabetic complications is already proven. However, it
remains to be determined to what extent the results are
affected by this bias.
Conclusions
Few concomitant treatments were published in this sam-
ple. There is a potential risk of observer bias in studies
assessing the efficacy of blood-glucose control in T2D.
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